论文部分内容阅读
目前观察重组人血管内皮抑制素注射液(恩度)联合化疗治疗多种晚期大肠癌的有效性和安全性。方法经病理组织学或细胞学检查确诊的晚期大肠癌18例。其中恩度15mg,加入生理盐水500mL中均速缓慢静脉滴注,第1至14天连续给药,间歇7天重复,21天一周期。结果全组18例患者中,15例患者可以评价客观疗效,获得PR2例,SD8例,PD5例,即客观有效率13.3%,疾病控制率为70.0%。结论恩度与化疗药物联合使用可以改善和稳定晚期大肠癌的生活质量,与部分化疗药物具有协同作用,安全性好,值得临床上推广应用和进一步深入形成。
Currently observe the effectiveness and safety of recombinant human endostatin injection (Endo) combined with chemotherapy for a variety of advanced colorectal cancer. Methods 18 cases of advanced colorectal cancer diagnosed by histopathology or cytology. Among them, Endostar 15mg, adding 500mL of normal saline in slow speed intravenous infusion, the first to 14 days continuous administration, intermittent 7 days repeat 21 days a cycle. Results Of the 18 patients, 15 patients could evaluate the objective curative effect. PR2, SD8 and PD5 were obtained. The objective effective rate was 13.3% and the disease control rate was 70.0%. Conclusions The combination of Endue and chemotherapeutic drugs can improve and stabilize the quality of life of advanced colorectal cancer and has synergistic effect with some chemotherapeutic drugs. It is safe and worthy of clinical application and further formation.